跳至主要内容
临床试验/NCT07398443
NCT07398443招募中不适用

Using Novel Behavioral Economic Measures to Characterize Dual Marijuana and Tobacco Use in Young Adults

Brown University1 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2026年2月17日最近更新:
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
120
试验地点
1
主要终点
Change in self-reported cannabis craving

研究概览

简要总结

The multi session experimental study aims to determine dual use patterns of marijuana and tobacco by assessing the impact of price and availability of marijuana and tobacco using a cross price elasticity of demand task. The study will recruit 120 non-treatment seeking emerging young adults (18-25 years) who smoke marijuana and tobacco.

详细描述

Young adulthood is a crucial time to study substance use disorders which increase cancer risk later in life. It is especially important to understand marijuana and tobacco use as most young adults often use both. Although dual use is related with increased long-term health and behavioral risks, underlying behavioral mechanisms remain unclear. This study aims to address this gap by using rigorous laboratory-based behavioral economic measure including a novel cross-price elasticity of demand (CPED) task and an innovative extension of cue-induced demand to assess cross-cue reactivity to better understand co- use. The results will help lead cessation efforts in this population and reduce cancer risk across the lifespan. Participants (N = 120) will be young adults (age 18-25) endorsing current tobacco and marijuana use and will complete 4 experimental in-person sessions. Following a phone-screen to assess preliminary eligibility, participants will come to the study center for in-person baseline screening. This screening consists of a urine toxicology screen, a breathalyzer test, and self-report questionnaires. The remaining three sessions will be completed in person which mainly consist of cross-cue reactivity sessions, self-report measures, and a qualitative exit interview following the final session.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 25 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Males/females who are 18 to 25 years of age
  • Young adults who currently smoke commercial tobacco cigarettes (≥1x weekly in the past 30 days and for the past six months)
  • Young adults who currently smoke marijuana (≥4 times in past 30 days and at least weekly on average for the last six months)
  • Participants must report purchasing their own tobacco and marijuana at least once in the past 6 months
  • Participants must speak, comprehend, and read English.

排除标准

  • Intention to quit marijuana or tobacco use in the next 30 days
  • Self-reported illicit drug or heavy episodic alcohol use on >20 days in the past month (excluding marijuana)
  • Individuals who are pregnant or breastfeeding
  • Positive saliva test for recent THC use
  • Breath alcohol level above 0 at any session.
  • Participants who exclusively roll their own tobacco cigarettes

研究组 & 干预措施

Cue Reactivity

Experimental

Participants will be exposed to neutral followed by cannabis or tobacco cues in a fixed sequence while they answer questions about their subjective state. The cues will include everyday items (e.g., eraser) and cannabis-related items (e.g., lighter).

干预措施: Cue Reactivity (Behavioral)

结局指标

主要结局

Change in self-reported cannabis craving

时间窗: Up to 40 days post-baseline session

This study utilizes a structured cannabis cue exposure paradigm. During cue exposure, participants rate subjective craving on a scale from 0, "Not at all," to 10, "Extremely." Cannabis craving will be assessed following neutral cue exposure and then cannabis cue exposure. The primary outcome will be change in cannabis craving.

Change in self-reported tobacco craving

时间窗: Up to 40 days post-baseline session

This study utilizes a structured tobacco cue exposure paradigm. During cue exposure, participants rate subjective craving on a scale from 0, "Not at all," to 10, "Extremely." Tobacco craving will be assessed following neutral cue exposure and then tobacco cue exposure. The primary outcome will be change in tobacco craving.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

进行中(未招募)
不适用
A Double-Blind, Double-Dummy, Placebo- and Active-Controlled Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-Inflammatory Effects of GSK1399686 in Patients with Mild to Moderately Active Ulcerative Colitis
EUCTR2009-011608-51-DEGlaxoSmithKline Research and Development Ltd.60
进行中(未招募)
1 期
A Double-Blind, Double-Dummy, Placebo- and Active-Controlled Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-Inflammatory Effects of GSK1399686 in Patients with Mild to Moderately Active Ulcerative Colitislcerative colitisMedDRA version: 9.1Level: LLTClassification code 10045365Term: Ulcerative colitis
EUCTR2009-011608-51-BEGlaxoSmithKline Research and Development Ltd60
进行中(未招募)
不适用
A Double-Blind, Double-Dummy, Placebo- and Active-Controlled Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-Inflammatory Effects of GSK1399686 in Patients with Mild to Moderately Active Ulcerative Colitis
EUCTR2009-011608-51-SEGlaxoSmithKline Research and Development Ltd60
进行中(未招募)
1 期
A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR administered orally over a 26-week maintenance phase in L-Dopa+ treated patients with advanced Parkinson’s disease (PD).
EUCTR2007-000074-23-CZBoehringer Ingelheim RCV GmbH & Co KG516
进行中(未招募)
不适用
A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR administered orally over a 26-week maintenance phase in patients with early Parkinson's disease (PD)
EUCTR2007-000073-39-HUBoehringer Ingelheim Pharma Ges mbH500